IMMUNOHISTOCHEMICAL EXPRESSION OF CTLA-4 IN CERVICAL CARCINOMA. | ||
| ALEXMED ePosters | ||
| Article 1, Volume 6, Issue 4, September 2024, Pages 74-75 | ||
| Document Type: Preliminary preprint short reports of original research | ||
| DOI: 10.21608/alexpo.2024.339988.2019 | ||
| Authors | ||
| Eman Mohamed ElSayed Emam1; Maram Allam2; Rowida Saad Ebrahim Habiba* 3 | ||
| 1Department of Pathology,* Faculty of Medicine, Alexandria University | ||
| 2Department of pathology, Faculty of Medicine,University of Alexandria. | ||
| 3Department of Pathology, Faculty of Medicine, University of Alexandria. | ||
| Abstract | ||
| Cervical cancer is the fourth most common cancer in females, accounting for 6.5% of total cancer incidence in women. It is also considered the most common gynecological cancer. The main cause of cervical cancer is a persistent infection with high-risk types of the human papillomavirus (HPV). P16 is considered a surrogate maker for high-risk human papillomavirus (hrHPV) infection. The standard management of cervical cancer, based on stage, histology, and patient-specific factors, encompasses a variety of strategies, including surgical interventions, radiotherapy, chemotherapy, and novel immunotherapies. Immune checkpoints including CTLA-4 are important molecules for immune system regulation & prevention of autoimmune diseases, but tumors can exploit them to evade anti-tumor immunity. CTLA-4 antibody can induce anti-tumor immunity, effectively amplifying T cells and enhancing the anti-tumor response. AIM: The aim of this study was to assess the immunohistochemical expression of CTLA-4 in cervical carcinoma in relation to histologic type, grade, stage and other clinicopathological parameters. | ||
| Keywords | ||
| CTLA-4; p16; CERVICAL CARCINOMA | ||
|
Supplementary Files
|
||
|
Statistics Article View: 4 |
||
